Gut Call On bluebird bio, Inc. (BLUE): Now It’s Really Up Too Much

bluebird bio, Inc. (NASDAQ:BLUE) is one of the hottest stocks trading today on the U.S. Markets as the company shares are 3.93% or 5.25 points higher from last closing price of $133.66, reaching $138.91 at last check. Any clue why there is so much of action in the BLUE stock? The share price has risen in 3 of the last 5 days and is down -12.82% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -17,395 shares, and in total 365805 shares valued at $50.814 million were seen changing hands compared with 383200 shares valued at $51.219 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in BLUE stock for the next couple of days.

bluebird bio, Inc. (BLUE) shares have notched a 3-month decline of about -12.82%, but has still advanced 34.74% year to date. By comparison, the stock sank -25.99% over the past 12 months, while it jumped 13.6% over the 1 month. The company’s market cap is around $7.35B, with its short interest ratio standing at 14.37%.

In the current trading session for BLUE, the stock witnessed two major price actions, it rose to a high of $139.45 and was down as much as $133.66 at one point. The high recorded is very low when compared to their 52-week high which is $87.49. The 52-week high is now at -23.47 distance from current price. Their recent low of $181.77 represents a 59% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for BLUE is $171, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of bluebird bio, Inc. earned $-11.36 per share in the trailing 12 months and has a P/E ratio of -12.23. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 98.29 and lower compared to the sector’s average of 34.16. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. BLUE also has P/S multiple of 149.4. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 41.94x.

The company recorded an interesting insider sale transaction by the Insider on Jul 05, 2019. A Securities and Exchanges Commission filings show that David Davidson sold a total of 7,660 BLUE shares that day for a sum of around $991,740. The filings show that the insider now retains 38,946 shares, currently worth $5,409,989. bluebird bio, Inc. (BLUE) insiders have acquired 6,612 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 27,541 shares. In total, individual insiders traded 34,153 shares in the business, which makes up 12.407% of 275,276 shares that were traded over a year. In the past 12 months, insiders have purchased 84,925 shares while the seller parted with 190,351 shares.

BLUE‘s last price was up 7.42% as compared to the average trading price of 50 days recorded at $129.31 while enlarging the period to 200 trading days, the average closing price was $125.64. At present, there are 54.96 million in the total number of common shares owned by the public and among those 54.84 million shares have been available to trade. The percentage of shares being held by the company management was 0.8% while institutions stake was 0%. The company has generated negative returns on equity over the last 12 months (-34%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the BLUE stock, there is another set of technicals that should be looked into and considered. Its 10.12% gain from moving average of $126.14 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.24 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of bluebird bio, Inc. — 10 analysts rate the stock as a buy with another 1 rating it strong buy. There are 8 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $157.2079 on shares of bluebird bio, Inc. (NASDAQ:BLUE), which corresponds to 13.10% upside potential than its current market price of $138.91 and implies potential despite the recent advance in the price. However, their current target price has fallen from $167.0569 a month ago and is down handily from the consensus target of $170.2607 a quarter ago.

In the last five years, the EPS of the company has been roughly -39.6%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 22 over the last five years. The company recently recorded a drop of -21.9%, but this figure is rather unattractive.